CN102958917B - 用于调节wnt信号通路的组合物和方法 - Google Patents

用于调节wnt信号通路的组合物和方法 Download PDF

Info

Publication number
CN102958917B
CN102958917B CN201180032354.9A CN201180032354A CN102958917B CN 102958917 B CN102958917 B CN 102958917B CN 201180032354 A CN201180032354 A CN 201180032354A CN 102958917 B CN102958917 B CN 102958917B
Authority
CN
China
Prior art keywords
compound
methyl
alkyl
mmol
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180032354.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102958917A (zh
Inventor
成岱
张国宝
韩东
高文奇
潘世风
L·沈
R·R·莱勒蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis International Pharmaceutical Ltd
Novartis AG
Original Assignee
IRM LLC
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44514972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102958917(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by IRM LLC, Novartis AG filed Critical IRM LLC
Publication of CN102958917A publication Critical patent/CN102958917A/zh
Application granted granted Critical
Publication of CN102958917B publication Critical patent/CN102958917B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Pyridine Compounds (AREA)
CN201180032354.9A 2010-06-29 2011-06-28 用于调节wnt信号通路的组合物和方法 Active CN102958917B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35956910P 2010-06-29 2010-06-29
US61/359,569 2010-06-29
PCT/US2011/042215 WO2012003189A1 (en) 2010-06-29 2011-06-28 Compositions and methods for modulating the wnt signaling pathway

Publications (2)

Publication Number Publication Date
CN102958917A CN102958917A (zh) 2013-03-06
CN102958917B true CN102958917B (zh) 2014-10-08

Family

ID=44514972

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180032354.9A Active CN102958917B (zh) 2010-06-29 2011-06-28 用于调节wnt信号通路的组合物和方法

Country Status (27)

Country Link
US (1) US9181235B2 (enExample)
EP (1) EP2588453B1 (enExample)
JP (1) JP5778270B2 (enExample)
KR (1) KR20130131290A (enExample)
CN (1) CN102958917B (enExample)
AR (1) AR082029A1 (enExample)
AU (1) AU2011271479B2 (enExample)
BR (1) BR112012033350A2 (enExample)
CA (1) CA2803879A1 (enExample)
CL (1) CL2012003604A1 (enExample)
CO (1) CO6650353A2 (enExample)
CU (1) CU20120174A7 (enExample)
DO (1) DOP2012000329A (enExample)
EA (1) EA201390032A1 (enExample)
EC (1) ECSP13012410A (enExample)
ES (1) ES2536216T3 (enExample)
MA (1) MA34388B1 (enExample)
MX (1) MX2012015092A (enExample)
NI (1) NI201200190A (enExample)
PE (1) PE20130311A1 (enExample)
PH (1) PH12012502571A1 (enExample)
SG (1) SG186473A1 (enExample)
TN (1) TN2012000575A1 (enExample)
TW (1) TW201206921A (enExample)
UY (1) UY33469A (enExample)
WO (1) WO2012003189A1 (enExample)
ZA (1) ZA201300319B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN105079805A (zh) 2008-09-26 2015-11-25 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
NZ602700A (en) 2010-04-01 2014-10-31 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
RU2486859C1 (ru) * 2012-02-02 2013-07-10 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения и социального развития Российской Федерации Способ оценки эффективности комбинированного органосохраняющего лечения первичной начальной ретинобластомы у детей
CN104379583B (zh) * 2012-06-15 2016-06-08 广州源生医药科技有限公司 作为wnt信号传导抑制剂的化合物、组合物及其应用
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
CA2922532C (en) * 2013-11-01 2023-09-19 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
DK3204378T6 (da) 2014-10-08 2022-07-18 Redx Pharma Plc N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
ES2922580T3 (es) * 2014-10-08 2022-09-16 Redx Pharma Plc Derivados de N-piridinilacetamida como inhibidores de la ruta de señalización WNT
CN104557862B (zh) * 2014-12-15 2017-05-17 苏州云轩医药科技有限公司 具有Wnt信号通路抑制活性的杂环化合物
CA3011685C (en) 2015-02-03 2021-07-20 Kadmon Pharmaceuticals, Llc Stable trientine formulations
US20180092866A1 (en) * 2015-04-15 2018-04-05 University Of Utah Research Foundation Substituted n-([1,1'-biphenyl]-3-yl)-[1,1'-biphenyl]-3-carboxamide analogs as inhibitors for beta-catenin/b-cell lymphoma 9 interactions
US20180112273A1 (en) * 2015-05-26 2018-04-26 Curegenix Corporation Tumor biomarkers and use thereof
CN107759584B (zh) * 2016-08-16 2021-06-01 苏州云轩医药科技有限公司 一种具有Wnt信号通路抑制活性的氨基五元杂环化合物及其应用
CN107056755B (zh) * 2015-12-07 2019-02-22 苏州信诺维医药科技有限公司 五元杂环酰胺类wnt通路抑制剂
WO2017097215A1 (zh) * 2015-12-07 2017-06-15 杭州雷索药业有限公司 内嵌脲类结构的wnt通路抑制剂
WO2017165839A1 (en) 2016-03-25 2017-09-28 University Of Utah Research Foundation Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/b-cell lymphoma 9 inhibitors
WO2018045182A1 (en) * 2016-09-01 2018-03-08 The Board Of Regents Of Hte University Of Texas System Disubstituted and trisubtituted 1,2,3-triazoles as wnt inhibitors
EP3717465A1 (en) * 2017-11-30 2020-10-07 Step Pharma S.A.S. Compounds
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN111662228B (zh) * 2019-03-07 2023-07-28 中国医学科学院药物研究所 吡啶酮酰联芳基胺类化合物及其用途
WO2020245664A1 (en) 2019-06-04 2020-12-10 Step Pharma S.A.S. N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
EP4438603A4 (en) 2021-11-25 2025-06-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
US20230399299A1 (en) * 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1741999A (zh) * 2002-11-19 2006-03-01 安万特医药德国有限公司 用作GSK－3β抑制剂的哒嗪酮衍生物
WO2009075874A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
WO2003093297A2 (en) * 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1713775A4 (en) * 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
EP1987004A2 (en) * 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
BRPI0714751A2 (pt) * 2006-09-08 2014-06-24 Genentech Inc "antagonistas wnt , composição , ácido nucléico , vetor , célula hospedeira , artigo manufaturado , método de inibição da sinalização wnt , método para detectar a presença de uam proteina wnt , método para modular a expressão de um gene wnt alvo em uma célula , método para tratar terapeuticamente um câncer mediado por wnt e usos de uns antagonistas wnt na manufatura de um medicamento "
US8247401B2 (en) 2007-10-31 2012-08-21 Merck Sharp & Dohme Corp. P2X3 receptor antagonists for treatment of pain
MX2010010209A (es) * 2008-03-18 2010-10-05 Merck Sharp & Dohme 4-hidroxipirimidina-5-carboxamidas sustituidas.
AU2009260503B2 (en) * 2008-05-27 2014-03-27 The Board Of Regents Of The University Of Texas System Wnt protein signalling inhibitors
US8384140B2 (en) 2008-07-29 2013-02-26 International Business Machines Corporation Structure for dual contact trench capacitor and structure thereof
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1741999A (zh) * 2002-11-19 2006-03-01 安万特医药德国有限公司 用作GSK－3β抑制剂的哒嗪酮衍生物
WO2009075874A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators

Also Published As

Publication number Publication date
ECSP13012410A (es) 2013-03-28
DOP2012000329A (es) 2013-07-15
AU2011271479A1 (en) 2013-02-07
TW201206921A (en) 2012-02-16
US20130079328A1 (en) 2013-03-28
ES2536216T3 (es) 2015-05-21
BR112012033350A2 (pt) 2016-11-29
CN102958917A (zh) 2013-03-06
JP2013533879A (ja) 2013-08-29
US9181235B2 (en) 2015-11-10
EP2588453B1 (en) 2015-04-01
EP2588453A1 (en) 2013-05-08
UY33469A (es) 2012-01-31
NI201200190A (es) 2013-04-15
TN2012000575A1 (en) 2014-04-01
AR082029A1 (es) 2012-11-07
CL2012003604A1 (es) 2013-03-22
MX2012015092A (es) 2013-03-05
CA2803879A1 (en) 2012-01-05
CU20120174A7 (es) 2013-04-19
AU2011271479B2 (en) 2014-08-14
JP5778270B2 (ja) 2015-09-16
KR20130131290A (ko) 2013-12-03
EA201390032A1 (ru) 2013-06-28
CO6650353A2 (es) 2013-04-15
PH12012502571A1 (en) 2020-10-19
MA34388B1 (fr) 2013-07-03
WO2012003189A1 (en) 2012-01-05
ZA201300319B (en) 2014-10-29
PE20130311A1 (es) 2013-03-23
SG186473A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
CN102958917B (zh) 用于调节wnt信号通路的组合物和方法
CN102369187B (zh) 用作wnt信号调节剂的n-(杂)芳基、2-(杂)芳基取代的乙酰胺类
EP2365752B1 (en) Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
JP6078640B2 (ja) Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
JP6461803B2 (ja) 置換ベンゼン化合物
JP6473420B2 (ja) 複素環スルホンアミド誘導体及びそれを含有する医薬
TW201011009A (en) Novel pyrrolidin-2-ones
TW201240968A (en) Arylamide derivatives as TTX-S blockers
RU2741000C2 (ru) Производное 1,4-дизамещенного имидазола
US20130317027A1 (en) Compounds and therapeutic uses thereof
EP3412664B1 (en) Heterocyclic sulfonamide derivative and medicine containing same
JP7673982B2 (ja) プロスタグランジンｅ２（ｐｇｅ２）ｅｐ４受容体アンタゴニスト
TW201229047A (en) Pyridone amide derivatives, preparation process and pharmaceutical use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: British Bermuda, Hamilton

Applicant after: IRM LLC

Applicant after: NOVARTIS AG

Address before: British Bermuda, Hamilton

Applicant before: IRM LLC

Applicant before: Novartis AG

C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160104

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: British Bermuda, Hamilton

Patentee before: Novartis international pharmaceuticals Ltd.

Patentee before: Novartis Ag

Effective date of registration: 20160104

Address after: British Bermuda, Hamilton

Patentee after: Novartis international pharmaceuticals Ltd.

Patentee after: NOVARTIS AG

Address before: British Bermuda, Hamilton

Patentee before: IRM LLC

Patentee before: Novartis Ag